NFKB1 and multiple sclerosis: Tofacitinib is a nanomolar inhibitor of Jak1-3 (Changelian et al., 2003) and MMF is a modulator of multiple cellular pathways including NFκB (Parodi et al., 2015; Mazzola et al., 2017) and Nrf2 (Linker et al., 2011); these compounds are FDA-approved for the treatment of rheumatoid arthritis and multiple sclerosis, respectively (Dhillon, 2017; Berger et al., 2021).